Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)
Status:
Terminated
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of azacitidine and
GM-CSF can help to control MDS. The safety of these drugs will also be studied.
Azacitidine is designed to block certain proteins that stop the function of tumor-fighting
genes. By blocking the "bad" proteins, the tumor-fighting genes may be able to work better.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is designed to help produce white
blood cells. This may help to fight infections.